Next-generation imaging development for nanoparticle biodistribution measurements.

As nanotechnologies move closer to use in humans, quantitative imaging methods will play a vital role in answering questions of biodistribution. Accurate knowledge of the location and quantity of in vivo nanoconstructs and carriers is a challenging task, and new methods of quantitative imaging at appropriate resolutions are being developed and tested. Sustaining simultaneous advancement in both imaging development and nanotechnology research requires multidisciplinary research teams conducting experiments with interconnected goals. On an even greater scale, networks of multidisciplinary teams focused on similar issues of imaging and probe development offer opportunities for leveraging resources, as well as providing a forum for sharing ideas and creating consensus on solutions to common challenges. The Network for Translational Research (NTR): Optical Imaging in Multimodal Platforms from the National Cancer Institute is just such a network. Four multidisciplinary centers are accepting the challenges of developing and optimizing multimodal imaging hardware and software along with imaging probe development. These efforts are similar to the efforts that will be required for future studies of in vivo nanoparticle biodistribution. In addition to technology development and optimization, the network is organized to confront the challenges of validation of the imaging hardware and associated imaging agents, similar to the methods needed for validating nanomedicine.

[1]  Shelton D Caruthers,et al.  Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. , 2006, Nanomedicine.

[2]  Grace Hu,et al.  Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.

[3]  Donghoon Lee,et al.  In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. , 2008, Small.

[4]  James J. Driscoll,et al.  Overall Survival: Still the Gold Standard: Why Overall Survival Remains the Definitive End Point in Cancer Clinical Trials , 2009, Cancer journal.

[5]  Shelton D Caruthers,et al.  Nanomedicine strategies for molecular targets with MRI and optical imaging. , 2010, Future medicinal chemistry.

[6]  Lesley Seymour,et al.  Tumor Shrinkage and Objective Response Rates: Gold Standard for Oncology Efficacy Screening Trials, or an Outdated End Point? , 2009, Cancer journal.

[7]  R Sankar,et al.  FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy , 2008, Neurology.

[8]  I-Chih Tan,et al.  Lymphatic imaging in humans with near-infrared fluorescence. , 2009, Current opinion in biotechnology.

[9]  S. Nofech-Mozes,et al.  Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard? , 2010, Gynecologic oncology.

[10]  M. Kashani-Sabet,et al.  Discordance in the histopathologic diagnosis of melanoma at a melanoma referral center. , 2010, Journal of the American Academy of Dermatology.

[11]  Ciprian Catana,et al.  Bimodal MR-PET agent for quantitative pH imaging. , 2010, Angewandte Chemie.

[12]  Jurgen Seidel,et al.  Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. , 2009, Bioconjugate chemistry.

[13]  Dorothy Farrell,et al.  The NCI Alliance for Nanotechnology in Cancer: achievement and path forward. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[14]  K. Washington,et al.  Assessment of Hepatic Steatosis by Expert Pathologists: The End of a Gold Standard , 2009, Annals of surgery.

[15]  Angelique Y. Louie,et al.  Core/shell quantum dots with high relaxivity and photoluminescence for multimodality imaging. , 2007 .

[16]  James R Baker,et al.  Dendrimer-based nanoparticles for cancer therapy. , 2009, Hematology. American Society of Hematology. Education Program.

[17]  Kerry K. Karukstis,et al.  Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.

[18]  Marcelino Bernardo,et al.  A dendrimer‐based nanosized contrast agent dual‐labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice , 2007, Journal of magnetic resonance imaging : JMRI.